Balchem (BCPC) to Release Earnings on Friday

Balchem (NASDAQ:BCPC) is set to issue its quarterly earnings data before the market opens on Friday, July 26th. Analysts expect the company to announce earnings of $0.94 per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings results on Friday, May 3rd. The basic materials company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $239.66 million for the quarter, compared to the consensus estimate of $234.12 million. Balchem had a return on equity of 11.03% and a net margin of 12.35%. On average, analysts expect Balchem to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Balchem Stock Down 2.6 %

BCPC stock opened at $174.95 on Thursday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.72 and a current ratio of 2.61. The company has a market capitalization of $5.67 billion, a price-to-earnings ratio of 49.42, a PEG ratio of 5.65 and a beta of 0.68. Balchem has a fifty-two week low of $110.74 and a fifty-two week high of $180.76. The stock has a fifty day moving average of $157.60 and a 200-day moving average of $151.70.

Insider Buying and Selling

In other news, SVP Michael Robert Sestrick sold 1,929 shares of Balchem stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $154.45, for a total value of $297,934.05. Following the sale, the senior vice president now directly owns 4,878 shares in the company, valued at approximately $753,407.10. The sale was disclosed in a filing with the SEC, which is available through this link. In other Balchem news, Director David B. Fischer sold 5,000 shares of Balchem stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $152.98, for a total transaction of $764,900.00. Following the completion of the transaction, the director now owns 9,009 shares in the company, valued at $1,378,196.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael Robert Sestrick sold 1,929 shares of Balchem stock in a transaction on Friday, May 10th. The shares were sold at an average price of $154.45, for a total value of $297,934.05. Following the transaction, the senior vice president now owns 4,878 shares of the company’s stock, valued at approximately $753,407.10. The disclosure for this sale can be found here. 1.25% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. HC Wainwright increased their price objective on Balchem from $167.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, May 6th. StockNews.com raised Balchem from a “hold” rating to a “buy” rating in a report on Friday, May 10th.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.